Ramucirumab biosimilar(Eden Biologics)

雷莫芦单抗生物类似药（Eden Biologics）

Report date: 2024/07/01 15:53:40

Base Information

Drug NameRamucirumab biosimilar(Eden Biologics)

Drug Alias NameJHL-1178EB-1001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonists

TargetsVascular endothelial growth factor receptor 2

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEden Biologics Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsColorectal Neoplasms

Inactive IndicationsN/A

ATC CodeN/A